Lead PI: Prof Geoff Donnan
Status: Closed to recruitment
No. of Patients Currently Recruited: 40
No. of Patients Required: 40
The purpose of this trial is to assess the efficacy and safety of S 44819 (150mg or 300mg twice per day) versus placebo in ischaemic stroke recovery. The primary objective of the study is to demonstrate the superiority of at least one of the two doses of S 44819 versus placebo on functional recovery from ischaemic stroke measured with the modified Rankin Scale (mRS) after 90 days of treatment.